Looks like the NIH's Preclinical Screening Program for Pain (PSPP) has been good to us, all paid for by NIH as well.
Emyria is able to strategically select target indications based on clinical insights within its proprietary Real-World Data set on more than 9,000 patients
Boom! 10K soon great growth on the RWD set feels like only yesterday we were at 5,000 then 8,000.
Ann: Emyria Unveils Highest Potency CBD Capsule for FDA Pathway, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.9¢ |
Change
0.001(3.57%) |
Mkt cap ! $17.73M | |||
| Open | High | Low | Value | Volume |
| 2.9¢ | 3.0¢ | 2.8¢ | $71.48K | 2.457M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 120800 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 1018286 | 4 |
View Market Depth
| Last trade - 15.42pm 15/07/2025 (20 minute delay) ? |
| EMD (ASX) Chart |